Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 10:10 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2449–2472 of 83,984 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: therapy Clear all
Completed Phase 3 Interventional

Risedronate 75mg Dosed on 2 Consecutive Days Monthly in the Treatment of Osteoporosis in Postmenopausal Women

NCT00358176
View directory record Official record
Conditions
Osteoporosis Postmenopausal
Interventions
Risedronate (HMR4003)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
50 Years and older · Female only
Enrollment
1,231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 15, 2009 · Synced Nov 3, 2026, 10:10 PM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

An Evidence-based Family Support Program for Parents and Children in Palestine: A Theory-based Intervention

NCT05706376
View directory record Official record
Conditions
Adolescent, Psychopathology, Parent-Child Relations, Violence
Interventions
Promoting Positive Family Futures, Treatment as Usual
Behavioral
Lead sponsor
University of Notre Dame
Other
Eligibility
12 Years to 75 Years
Enrollment
900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Notre Dame, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Nov 3, 2026, 10:10 PM EST
Terminated Not applicable Interventional Results available

Thalamic Deep Brain Stimulation for the Treatment of Refractory Tourette Syndrome

NCT01817517
View directory record Official record
Conditions
Tourette Syndrome
Interventions
Medtronic Activa Deep Brain Stimulation System
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
15 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Nov 3, 2026, 10:10 PM EST
Recruiting Not applicable Interventional

Using Non-invasive Brain Stimulation to Treat Word Finding Difficulty in Chronic Traumatic Brain Injury

NCT06848140
View directory record Official record
Conditions
Traumatic Brain Injury, Word Finding Difficulty, Cognitive Symptom, Cognitive Change, Acquired Brain Injury
Interventions
Active Transcranial direct current stimulation, Sham Transcranial direct current stimulation
Device
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Nov 3, 2026, 10:10 PM EST
Completed Phase 4 Interventional Results available

Adjunctive Topiramate for Treatment of Alcohol Dependence in Patients With Bipolar Disorder

NCT00572117
View directory record Official record
Conditions
Bipolar Disorder, Alcoholism, Alcohol Dependence
Interventions
Topiramate
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Nov 3, 2026, 10:10 PM EST
Terminated Phase 1 Interventional

Hyperthermia and Olaparib in Treating Breast Cancer Patients With Chest Wall Recurrences

NCT03955640
View directory record Official record
Conditions
Metastatic Malignant Neoplasm in the Chest Wall, Recurrent Breast Carcinoma
Interventions
Olaparib, Hyperthermia Treatment, Questionnaire Administration, Quality-of-Life Assessment
Drug · Procedure · Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Nov 3, 2026, 10:10 PM EST
Completed Not applicable Interventional

A Brief Intervention for Chronic Pain in Primary Care

NCT03692468
View directory record Official record
Conditions
Chronic Pain
Interventions
Psychotherapy
Behavioral
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 7, 2022 · Synced Nov 3, 2026, 10:10 PM EST
Completed Phase 2 Interventional Accepts healthy volunteers

Antidepressant Treatment of Mexican-Americans: UCLA Pharmacogenetics and Pharmacogenomics Research Group

NCT00265291
View directory record Official record
Conditions
Major Depressive Disorder, Major Depression, Unipolar Depression
Interventions
fluoxetine or desipramine
Drug
Lead sponsor
National Institute of General Medical Sciences (NIGMS)
NIH
Eligibility
18 Years to 70 Years
Enrollment
700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2008
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 10, 2008 · Synced Nov 3, 2026, 10:10 PM EST
Recruiting Phase 3 Interventional

A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

NCT06819891
View directory record Official record
Conditions
Moderately to Severely Active Crohns Disease
Interventions
Afimkibart, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
16 Years to 80 Years
Enrollment
425 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
64
States / cities
Dothan, Alabama • Glendale, Arizona • Lancaster, California + 57 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Nov 3, 2026, 10:10 PM EST
Completed Not applicable Interventional Results available

A Study Evaluating an Advanced Pneumatic Compression Device Versus Usual Care for Treatment of Head and Neck Lymphedema

NCT04797390
View directory record Official record
Conditions
Lymphedema, Lymphedema of Face, Lymphedema, Secondary, Lymphedema Due to Radiation, Lymphedema; Surgical
Interventions
Advanced Pneumatic Compression Device (APCD), Usual Care
Device · Other
Lead sponsor
Tactile Medical
Industry
Eligibility
18 Years and older
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
10
States / cities
Birmingham, Alabama • Chicago, Illinois • Louisville, Kentucky + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Nov 3, 2026, 10:10 PM EST
Withdrawn Phase 4 Interventional

ACTHAR Therapy for Central Nervous System Sarcoidosis

NCT02920710
View directory record Official record
Conditions
Sarcoidosis
Interventions
Repository Corticotropin Injection
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 20, 2020 · Synced Nov 3, 2026, 10:10 PM EST
Completed Phase 3 Interventional Results available

Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate and Fluticasone Propionate in People With Asthma

NCT01436110
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone furoate 50mcg, Fluticasone propionate 100mcg, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
20
States / cities
Los Angeles, California • Rolling Hills Estates, California • Sacramento, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Nov 3, 2026, 10:10 PM EST
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effects of Smoking Environments on Brain Reactivity

NCT03421210
View directory record Official record
Conditions
Cigarette Smoking
Interventions
Nicotine patch
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Nov 3, 2026, 10:10 PM EST
Not yet recruiting Phase 3 Interventional

Long-Term Efficacy Study of Vatiquinone for the Treatment of Friedreich's Ataxia (FA)

NCT07681713
View directory record Official record
Conditions
Friedreich's Ataxia
Interventions
Vatiquinone
Drug
Lead sponsor
PTC Therapeutics
Industry
Eligibility
7 Years to 21 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
4
States / cities
Los Angeles, California • Tampa, Florida • Iowa City, Iowa + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Nov 3, 2026, 10:10 PM EST
Completed Phase 2 Interventional Results available

Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Participants With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS)

NCT03441360
View directory record Official record
Conditions
Relapsed/Refractory Rhabdomyosarcoma, Non-rhabdomyosarcoma Soft Tissue Sarcoma, Ewing Sarcoma
Interventions
Eribulin mesylate
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
12 Months to 18 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
41
States / cities
Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 36 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2022 · Synced Nov 3, 2026, 10:10 PM EST
Withdrawn No phase listed Observational Accepts healthy volunteers

A Time-Limited Approach to Treatment With Ibrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

NCT04694560
View directory record Official record
Conditions
CLL, SLL, CLL/SLL, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Treatment Free Observation
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
2
States / cities
Monroe, North Carolina • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Nov 3, 2026, 10:10 PM EST
Terminated Phase 1 Interventional

An Exploratory Trial of Ketamine for the Treatment of Rett Syndrome

NCT02562820
View directory record Official record
Conditions
Rett Syndrome
Interventions
Intravenous infusion
Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
5 Years to 25 Years · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 30, 2017 · Synced Nov 3, 2026, 10:10 PM EST
Not yet recruiting Phase 1 Interventional

211At-MABG in Adults With Advanced Neuroendocrine Cancers

NCT07661420
View directory record Official record
Conditions
Pheochromocytoma, Paraganglioma, Neuroendocrine Tumors, Medullary Thyroid Cancer, Bronchial Carcinoid, Gastroenteropancreatic Neuroendocrine Neoplasm
Interventions
1 MBq/k of 211At-MABG Fractionated, 2 MBq/k1 of 211At-MABG Fractionated, 4 MBq/k of 211At-MABG Fractionated
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Nov 3, 2026, 10:10 PM EST
Terminated Phase 3 Interventional

RHB-204 for the Treatment of Pulmonary Mycobacterium Avium Complex Disease

NCT04616924
View directory record Official record
Conditions
Pulmonary Mycobacterium Avium Complex Infection, Bronchiectasis, Lung Diseases
Interventions
RHB-204, Placebo
Drug
Lead sponsor
RedHill Biopharma Limited
Industry
Eligibility
18 Years to 85 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
25
States / cities
Glendale, California • Palm Springs, California • Farmington, Connecticut + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Nov 3, 2026, 10:10 PM EST
Completed Phase 2 Interventional

A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Sensitive Recurrent Ovarian Cancer

NCT01033123
View directory record Official record
Conditions
Ovarian Cancer
Interventions
BSI-201
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older · Female only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 17, 2016 · Synced Nov 3, 2026, 10:10 PM EST
Terminated Phase 3 Interventional Results available

Safety and Efficacy of Apligraf in Nonhealing Wounds of Subjects With Junctional or Dystrophic Epidermolysis Bullosa (EB)

NCT00587223
View directory record Official record
Conditions
Epidermolysis Bullosa, Junctional, Epidermolysis Bullosa Dystrophica
Interventions
Apligraf, Standard dressing regimen
Device · Other
Lead sponsor
Organogenesis
Industry
Eligibility
2 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
5
States / cities
Stanford, California • Miami, Florida • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2010 · Synced Nov 3, 2026, 10:10 PM EST
Active, not recruiting Not applicable Interventional

Randomized Controlled Trial of Alert-Based Computerized Decision Support for Optimizing Low-Density Lipoprotein Management

NCT05088759
View directory record Official record
Conditions
Hyperlipemia, Mixed, ASCVD
Interventions
Alert
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Nov 3, 2026, 10:10 PM EST
Recruiting Phase 2 Interventional

Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease

NCT05907759
View directory record Official record
Conditions
Lymphoma, Primary Effusion
Interventions
Daratumumab SC
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2035
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 3, 2026, 10:10 PM EST
Completed Phase 3 Interventional

Phase III Trial of Dantonic® (T89) Capsule to Prevent and Treat Stable Angina

NCT01659580
View directory record Official record
Conditions
Angina Pectoris
Interventions
T89 high dose, T89 Low dose, Sanqi+Bingpian, Placebo
Drug
Lead sponsor
Tasly Pharmaceuticals, Inc.
Industry
Eligibility
20 Years to 80 Years
Enrollment
1,004 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
30
States / cities
Little Rock, Arkansas • Banning, California • La Jolla, California + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2017 · Synced Nov 3, 2026, 10:10 PM EST